Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Chinook Therapeutics Inc.

    NASDAQ: KDNY · Real-Time Price · USD
    40.39
    0.09 (0.22%)
    At close: Aug 10, 2023, 8:00 PM

    Chinook Therapeutics Statistics

    Share Statistics

    Chinook Therapeutics has 67.05M shares outstanding. The number of shares has increased by 43.31% in one year.

    Shares Outstanding

    n/a
    		 67.05M

    Shares Change (YoY)

    n/a
    		 43.31%

    Shares Change (QoQ)

    n/a
    		 3.79%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 2,992

    FTD / Avg. Volume

    n/a
    		 0.15%

    Short Selling Information

    The latest short interest is 2.88M, so 4.01% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 2.88M

    Short % of Shares Out

    n/a
    		 4.01%

    Short % of Float

    n/a
    		 4.59%

    Short Ratio (days to cover)

    n/a
    		 3.45

    Valuation Ratios

    The PE ratio is -9.14 and the forward PE ratio is null. Chinook Therapeutics's PEG ratio is -0.31.

    PE Ratio

    n/a
    		 -9.14

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 275.21

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 3.82

    P/FCF Ratio

    n/a
    		 -14.16

    PEG Ratio

    n/a
    		 -0.31
    Financial Ratio History

    Enterprise Valuation

    Chinook Therapeutics has an Enterprise Value (EV) of 1.61B.

    EV / Sales

    n/a
    		 262.81

    EV / EBITDA

    n/a
    		 -9.81

    EV / EBIT

    n/a
    		 -13.71

    EV / FCF

    n/a
    		 -13.52

    Financial Position

    The company has a current ratio of 7.59, with a Debt / Equity ratio of 0.09.

    Current Ratio

    n/a
    		 7.59

    Quick Ratio

    n/a
    		 7.59

    Debt / Equity

    n/a
    		 0.09

    Debt / EBITDA

    n/a
    		 -0.24

    Debt / FCF

    n/a
    		 -0.33

    Interest Coverage

    n/a
    		 -25.78

    Financial Efficiency

    Return on Equity is -41.77% and Return on Invested Capital is -39.37%.

    Return on Equity

    n/a
    		 -41.77%

    Return on Assets

    n/a
    		 -32.16%

    Return on Invested Capital

    n/a
    		 -39.37%

    Revenue Per Employee

    n/a
    		 $28,635.51

    Profits Per Employee

    n/a
    		 $-862,686.92

    Employee Count

    n/a
    		 214

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 4.34M

    Effective Tax Rate

    n/a
    		 -2.41%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 0.67, so Chinook Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.67

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 38.59

    200-Day Moving Average

    n/a
    		 26.93

    Relative Strength Index (RSI)

    n/a
    		 78.49

    Average Volume (20 Days)

    n/a
    		 2,044,466

    Income Statement

    In the last 12 months, Chinook Therapeutics had revenue of 6.13M and earned -184.62M in profits. Earnings per share was -2.87.

    Revenue

    n/a
    		 6.13M

    Gross Profit

    n/a
    		 4.41M

    Operating Income

    n/a
    		 -185.08M

    Net Income

    n/a
    		 -184.62M

    EBITDA

    n/a
    		 -164.2M

    EBIT

    n/a
    		 -173.1M

    Earnings Per Share (EPS)

    n/a
    		 -2.87
    Full Income Statement

    Balance Sheet

    The company has 115.44M in cash and 39.44M in debt, giving a net cash position of 76M.

    Cash & Cash Equivalents

    n/a
    		 115.44M

    Total Debt

    n/a
    		 39.44M

    Net Cash

    n/a
    		 76M

    Retained Earnings

    n/a
    		 -419.63M

    Total Assets

    n/a
    		 488.81M

    Working Capital

    n/a
    		 252.94M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -117.48M and capital expenditures -1.65M, giving a free cash flow of -119.13M.

    Operating Cash Flow

    n/a
    		 -117.48M

    Capital Expenditures

    n/a
    		 -1.65M

    Free Cash Flow

    n/a
    		 -119.13M

    FCF Per Share

    n/a
    		 -1.85
    Full Cash Flow Statement

    Margins

    Gross margin is 71.9%, with operating and profit margins of -3020.28% and -3012.65%.

    Gross Margin

    n/a
    		 71.9%

    Operating Margin

    n/a
    		 -3020.28%

    Pretax Margin

    n/a
    		 -2941.81%

    Profit Margin

    n/a
    		 -3012.65%

    EBITDA Margin

    n/a
    		 -2679.44%

    EBIT Margin

    n/a
    		 -3020.28%

    FCF Margin

    n/a
    		 -1944.09%

    Dividends & Yields

    KDNY does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -10.95%

    FCF Yield

    n/a
    		 -7.06%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for KDNY.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Oct 2, 2020. It was a backward split with a ratio of 1:5.

    Last Split Date

    n/a
    		 Oct 2, 2020

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:5

    Scores

    Altman Z-Score

    n/a
    		 9.7

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist